DIASORIN EARNED CE-MARK EXTENDING SAMPLE CLAIMS FOR DIASORIN MOLECULAR’S SIMPLEXA HSV 1 & 2 KIT

September 21, 2017, Saluggia (VC) - DiaSorin (FTSE Italia Mid Cap: DIA) announced today, it has earned CE-Mark extending the sample claims for its Simplexa™ HSV 1&2 assay.

The Simplexa HSV 1&2 Direct Kit is a real-time PCR assay, run on the 8 well Direct Amplification Disc for use on the LIAISON® MDX instrument for the in vitro qualitative detection and differentiation of HSV-1 and HSV-2.

The extension adds – cutaneous and mucocutaneous lesion swabs – to previously claimed specimen types of cerebrospinal fluid (CSF) and genital swabs. The test provides sample to answer workflow with flexibility to process as little as one and up to eight samples at a time.

Herpes Simplex Viruses (1&2) can cause a variety of diseases with multiple presentations, ranging from mucocutaneous oral and genital lesions to fulminate encephalitis. The coverage of multiple sample types allows laboratories to accommodate various HSV testing needs with one assay.

HSV central nervous system infection can reach mortality rates as high as 70% and globally there are an estimated 3.7 billion HSV-1 and 417 million HSV-2 infections.

Rapid testing for HSV infection using molecular detection can impact therapeutic decision making and may help prevent transmission.

“The expansion of our sample claim gives laboratories the most comprehensive HSV PCR test available, enabling testing of multiple samples with one kit, without DNA extraction,” said Michelle Tabb, Vice President of Research and Development, DiaSorin Molecular. “We are pleased to expand our offerings of simple, flexible assays to accommodate the shifting needs of today’s laboratories.”

About DiaSorin
Headquartered in Italy and listed in the FTSE Italia Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the diagnostic field to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostic market and a broad number of molecular diagnostic tests, which identify DiaSorin Group as the IVD “diagnostics specialist”.

For additional information, please contact:

Riccardo Fava
Investor Relations & Corporate Communication Senior Director
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Ines Di Terlizzi
Investor Relator
Tel: +39.0161.487567
ines.diterlizzi@diasorin.it